Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE A GARCIA ZUAZAGA

Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery

NPI
1407979529
CMS profile
830298
Location
CONCORD TOWNSHIP, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,421.43

52 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE A GARCIA ZUAZAGA

NPI 1407979529 · CMS profile ID 830298

Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery

CONCORD TOWNSHIP, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407979529?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407979529?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407979529?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1407979529?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

52 matching records · $2,421.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 52 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–52 of 52.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $217.4501/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201901789 CMS
ABBVIE INC. $17.6901/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201901787 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,268.57 21
PY2020 $1,238.59 7
PY2021 $12,408.53 45
PY2022 $24,381.63 42
PY2023 $84,667.07 52
PY2024 $16,980.08 79
PY2025 $2,421.43 52

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,893,327.58 407
PY2024 Principal investigator $2,667,688.93 422
PY2023 Recipient $18,196.50 3
PY2023 Principal investigator $882,864.23 139
PY2022 Principal investigator $164,380.88 32
PY2021 Recipient $18,912.00 5
PY2021 Principal investigator $12,300.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

407 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $37,500.00 12/26/2025 Non-covered Recipient Entity
Apex Clinical Research
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1235998993
Principal investigator 1 Janssen Research & Development, LLC $15,541.00 12/25/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419159
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $37,500.00 12/24/2025 Non-covered Recipient Entity
Apex Dermatology And Skin Surgery Center, Llc
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1235998979
Principal investigator 1 ABBVIE INC. $750.00 12/23/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202531796
Principal investigator 1 SANOFI US SERVICES INC. $491.50 12/22/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145945
Principal investigator 1 Incyte Corporation $57.00 12/19/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503240
Principal investigator 1 Incyte Corporation $57.00 12/19/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503244
Principal investigator 1 Incyte Corporation $57.00 12/19/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503247
Principal investigator 1 Incyte Corporation $2,120.00 12/19/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503257
Principal investigator 1 Incyte Corporation $2,309.00 12/19/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503264
Principal investigator 1 Incyte Corporation $3,120.00 12/19/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503285
Principal investigator 1 Incyte Corporation $824.50 12/17/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503299
Principal investigator 1 PFIZER INC. $9,073.36 12/17/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228746591
Principal investigator 1 ABBVIE INC. $2,297.00 12/16/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202530654
Principal investigator 1 PFIZER INC. $514.56 12/16/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228736615
Principal investigator 1 PFIZER INC. $6,606.23 12/16/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228748873
Principal investigator 1 Janssen Research & Development, LLC $877.00 12/15/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419081
Principal investigator 1 SANOFI US SERVICES INC. $8,530.00 12/15/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145949
Principal investigator 1 ABBVIE INC. $1,167.55 12/11/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202530200
Principal investigator 1 PFIZER INC. $11,000.48 12/11/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228749177
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $179,017.64 12/10/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289500
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $89,167.60 12/10/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289504
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $947.00 12/10/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289526
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $495.00 12/10/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289528
Principal investigator 1 ABBVIE INC. $1,694.00 12/09/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202529748
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 12/08/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145930
Principal investigator 1 SANOFI US SERVICES INC. $679.00 12/08/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145934
Principal investigator 1 SANOFI US SERVICES INC. $2,812.50 12/08/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145938
Principal investigator 1 ABBVIE INC. $32,376.58 12/04/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202528380
Principal investigator 1 ABBVIE INC. $8,107.08 12/04/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202528432
Principal investigator 1 ABBVIE INC. $6,498.72 12/04/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202528434
Principal investigator 1 ABBVIE INC. $1,988.25 12/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202526302
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,950.00 12/01/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288969
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,648.51 12/01/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289093
Principal investigator 1 ABBVIE INC. $160.80 11/25/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202525368
Principal investigator 1 PFIZER INC. $800.00 11/25/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228737142
Principal investigator 1 SANOFI US SERVICES INC. $3,321.90 11/24/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145941
Principal investigator 1 ABBVIE INC. $506.25 11/20/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202525024
Principal investigator 1 ABBVIE INC. $2,500.00 11/18/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202524511
Principal investigator 1 PFIZER INC. $10,950.00 11/18/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228729226
Principal investigator 1 SANOFI US SERVICES INC. $3,011.00 11/17/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145919
Principal investigator 1 SANOFI US SERVICES INC. $616.00 11/17/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145922
Principal investigator 1 SANOFI US SERVICES INC. $821.00 11/17/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145925
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,035.93 11/14/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223288361
Principal investigator 1 PFIZER INC. $2,660.18 11/13/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228724090
Principal investigator 1 ABBVIE INC. $742.50 11/10/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523703
Principal investigator 1 ABBVIE INC. $711.10 11/06/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523235
Principal investigator 1 ABBVIE INC. $16,237.20 11/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202521639
Principal investigator 1 ABBVIE INC. $33,661.64 11/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202521657
Principal investigator 1 ABBVIE INC. $4,509.78 11/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202523023
Principal investigator 1 Incyte Corporation $108.00 11/05/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503222
Principal investigator 1 Incyte Corporation $51.00 11/05/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503230
Principal investigator 1 Incyte Corporation $162.00 11/05/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503234
Principal investigator 1 Incyte Corporation $86.00 11/05/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503250
Principal investigator 1 Incyte Corporation $756.00 11/05/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503272
Principal investigator 1 Incyte Corporation $1,950.00 11/05/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503289
Principal investigator 1 Incyte Corporation $135.00 11/05/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503293
Principal investigator 1 Incyte Corporation $135.00 11/05/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503296
Principal investigator 1 ABBVIE INC. $4,036.08 11/04/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202520259
Principal investigator 1 PFIZER INC. $2,500.00 11/04/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228723816
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $99,130.61 11/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287873
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $297.00 11/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $275.00 11/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287921
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Apex Dermatology And Skin Surgery Center, Llc
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235998981
Principal investigator 1 ABBVIE INC. $726.30 10/29/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202519615
Principal investigator 1 Janssen Research & Development, LLC $2,783.00 10/24/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419097
Principal investigator 1 ABBVIE INC. $1,200.00 10/22/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202518149
Principal investigator 1 Incyte Corporation $108.00 10/22/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503226
Principal investigator 1 Incyte Corporation $3,481.00 10/22/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503268
Principal investigator 1 Incyte Corporation $57.00 10/22/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503276
Principal investigator 1 Incyte Corporation $1,349.50 10/22/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503280
Principal investigator 1 Incyte Corporation $2,425.00 10/22/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503305
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,950.00 10/22/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287237
Principal investigator 1 ABBVIE INC. $1,086.00 10/15/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202517011
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,400.00 10/15/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286985
Principal investigator 1 SANOFI US SERVICES INC. $441.50 10/14/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145910
Principal investigator 1 SANOFI US SERVICES INC. $593.00 10/14/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145914
Principal investigator 1 PFIZER INC. $847.80 10/11/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228741765
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,692.00 10/10/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286695
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $385.00 10/10/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286697
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,564.00 10/10/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286699
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $715.00 10/10/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286701
Principal investigator 1 ABBVIE INC. $3,631.24 10/09/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202515971
Principal investigator 1 ABBVIE INC. $23,544.71 10/09/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202515973
Principal investigator 1 Janssen Research & Development, LLC $1,304.00 10/09/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419092
Principal investigator 1 Janssen Research & Development, LLC $375.00 10/08/2025 Non-covered Recipient Entity
Apex Derm Mayfield Hts
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175261008
Principal investigator 1 Janssen Research & Development, LLC $200.00 10/08/2025 Non-covered Recipient Entity
Apex Derm Mayfield Hts
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175261226
Principal investigator 1 Janssen Research & Development, LLC $200.00 10/08/2025 Non-covered Recipient Entity
Apex Derm Mayfield Hts
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175261251
Principal investigator 1 Janssen Research & Development, LLC $800.00 10/08/2025 Non-covered Recipient Entity
Apex Derm Mayfield Hts
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175261650
Principal investigator 1 Novartis Pharmaceuticals Corporation $322,777.32 10/08/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER, LLC
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190312931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 10/08/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223286555
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,950.00 10/08/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223286559
Principal investigator 1 Janssen Research & Development, LLC $832.00 10/06/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419143
Principal investigator 1 SANOFI US SERVICES INC. $2,034.90 10/06/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,131.97 10/01/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286111
Principal investigator 1 ABBVIE INC. $1,350.65 09/30/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202512790
Principal investigator 1 Janssen Research & Development, LLC $4,596.00 09/29/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419119
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $594.00 09/26/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285927
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $650.00 09/26/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285929
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $165.00 09/26/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,346.00 09/26/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285933
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $55.00 09/26/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,764.60 09/26/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285963
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 09/25/2025 Non-covered Recipient Entity
Apex Derm Mayfield Hts
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175261170
Principal investigator 1 PFIZER INC. $6,660.20 09/24/2025 Non-covered Recipient Entity
Jorge GarciaZuazaga
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228750766
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $550.00 09/24/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285864
Principal investigator 1 SANOFI US SERVICES INC. $6,031.50 09/22/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145897
Principal investigator 1 SANOFI US SERVICES INC. $4,515.00 09/22/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145902
Principal investigator 1 ABBVIE INC. $8,725.00 09/18/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202511312
Principal investigator 1 ABBVIE INC. $430.14 09/16/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202510990
Principal investigator 1 ABBVIE INC. $742.50 09/15/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202510898
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $187.60 09/12/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285359
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,000.00 09/12/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285361
Principal investigator 1 ABBVIE INC. $4,000.00 09/10/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202510396
Principal investigator 1 PFIZER INC. $32,119.91 09/09/2025 Non-covered Recipient Entity
Jorge GarciaZuazaga
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228758427
Principal investigator 1 ABBVIE INC. $1,056.37 09/08/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202510222
Principal investigator 1 Janssen Research & Development, LLC $7,283.00 09/08/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419150
Principal investigator 1 Incyte Corporation $4,000.00 09/05/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503210
Principal investigator 1 Incyte Corporation $5,000.00 09/05/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503214
Principal investigator 1 Incyte Corporation $28,000.00 09/05/2025 Non-covered Recipient Entity
APEX DERMATOLOGY MAYFIELD HEIGHTS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240503218
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $891.00 09/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285149
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $297.00 09/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285151
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $165.00 09/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285153
Principal investigator 1 ABBVIE INC. $24,950.00 09/04/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202508464
Principal investigator 1 ABBVIE INC. $6,383.94 09/04/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202508554
Principal investigator 1 ABBVIE INC. $27,392.63 09/04/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202508652
Principal investigator 1 PFIZER INC. $1,686.16 09/03/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228758943
Principal investigator 1 SANOFI US SERVICES INC. $400.00 09/03/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145887
Principal investigator 1 SANOFI US SERVICES INC. $3,163.50 09/03/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145894
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $21,589.42 09/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284895
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $250.00 09/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284997
Principal investigator 1 ABBVIE INC. $1,844.00 09/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202506905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $330.00 09/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284755
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 09/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284757
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 09/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284759
Principal investigator 1 ABBVIE INC. $742.50 08/27/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505975
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 08/27/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284653
Principal investigator 1 SANOFI US SERVICES INC. $441.50 08/25/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145890
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $30,126.63 08/22/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284525
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,950.00 08/22/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284551
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,400.00 08/20/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284435
Principal investigator 1 ABBVIE INC. $2,780.00 08/19/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505071
Principal investigator 1 SANOFI US SERVICES INC. $3,715.00 08/18/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145871
Principal investigator 1 SANOFI US SERVICES INC. $5,593.00 08/18/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145876
Principal investigator 1 ABBVIE INC. $1,923.75 08/13/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202504355
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,950.00 08/13/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284169
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 08/13/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284171
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 08/13/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284173
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $220.00 08/13/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284175
Principal investigator 1 ABBVIE INC. $750.00 08/12/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202504225
Principal investigator 1 SANOFI US SERVICES INC. $3,828.38 08/11/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145882
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,579.00 08/08/2025 Non-covered Recipient Entity
Apex Clinical Research Center, Llc
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis No dispute reported 06/30/2026 1235998983
Principal investigator 1 ABBVIE INC. $3,637.10 08/06/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202502480
Principal investigator 1 ABBVIE INC. $58,581.47 08/06/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202502482
Principal investigator 1 ABBVIE INC. $3,510.80 08/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202501392
Principal investigator 1 SANOFI US SERVICES INC. $1,163.00 08/04/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145862
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 08/04/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,159.04 08/01/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283379
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,986.80 08/01/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283381
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $330.00 08/01/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283583
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,861.36 08/01/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283617
Principal investigator 1 Janssen Research & Development, LLC $16,078.00 07/31/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419132
Principal investigator 1 ABBVIE INC. $445.50 07/24/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202499566
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 07/23/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283030
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 07/23/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283032
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,617.65 07/23/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283040
Principal investigator 1 ABBVIE INC. $160.80 07/17/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202498608
Principal investigator 1 ABBVIE INC. $381.90 07/17/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202498612
Principal investigator 1 ABBVIE INC. $144.68 07/17/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202498614
Principal investigator 1 ABBVIE INC. $520.00 07/17/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202498616
Principal investigator 1 ABBVIE INC. $1,996.50 07/17/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202498652
Principal investigator 1 SANOFI US SERVICES INC. $3,843.00 07/14/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145850
Principal investigator 1 SANOFI US SERVICES INC. $8,761.00 07/14/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145856
Principal investigator 1 Janssen Research & Development, LLC $3,822.00 07/11/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419105
Principal investigator 1 PFIZER INC. $10,000.00 07/11/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228773672
Principal investigator 1 Janssen Research & Development, LLC $1,135.00 07/07/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419086
Principal investigator 1 Janssen Research & Development, LLC $652.00 07/07/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419128
Principal investigator 1 Janssen Research & Development, LLC $3,661.00 07/07/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419154
Principal investigator 1 SANOFI US SERVICES INC. $3,828.38 07/07/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145858
Principal investigator 1 ABBVIE INC. $12,896.68 07/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202495123
Principal investigator 1 ABBVIE INC. $33,519.60 07/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202495125
Principal investigator 1 ABBVIE INC. $1,378.86 07/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202495183
Principal investigator 1 ABBVIE INC. $2,292.50 07/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202495185
Principal investigator 1 SANOFI US SERVICES INC. $5,565.70 07/02/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145852
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,103.74 07/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282204
Principal investigator 1 Janssen Research & Development, LLC $13,526.00 06/27/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419113
Principal investigator 1 ABBVIE INC. $2,250.00 06/26/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202493265
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $275.00 06/25/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223281888
Principal investigator 1 Janssen Research & Development, LLC $814.00 06/24/2025 Non-covered Recipient Entity
Apex Derm Mayfield Hts
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175261284
Principal investigator 1 Janssen Research & Development, LLC $832.00 06/23/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419138
Principal investigator 1 Janssen Research & Development, LLC $574.00 06/20/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260969
Principal investigator 1 Janssen Research & Development, LLC $2,363.00 06/20/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260984
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 06/20/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261020
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 06/20/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261149
Principal investigator 1 Janssen Research & Development, LLC $205.00 06/20/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261275
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/20/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261292
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/20/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261306
Principal investigator 1 Janssen Research & Development, LLC $574.00 06/20/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261719
Principal investigator 1 ABBVIE INC. $1,336.50 06/18/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202492241
Principal investigator 1 ABBVIE INC. $1,925.90 06/17/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202491831
Principal investigator 1 SANOFI US SERVICES INC. $492.00 06/16/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145844
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 06/13/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223281230
Principal investigator 1 Janssen Research & Development, LLC $1,150.00 06/10/2025 Non-covered Recipient Entity
Apex Derm Mayfield Hts
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175261186
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 06/10/2025 Non-covered Recipient Entity
Apex Derm Mayfield Hts
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175261556
Principal investigator 1 Janssen Research & Development, LLC $37,000.00 06/09/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175419123
Principal investigator 1 SANOFI US SERVICES INC. $5,597.18 06/09/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145841
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $60,530.51 06/06/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280944
Principal investigator 1 Janssen Research & Development, LLC $201.00 06/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261013
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 06/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261162
Principal investigator 1 Janssen Research & Development, LLC $2,363.00 06/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261341
Principal investigator 1 Janssen Research & Development, LLC $50.00 06/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261520
Principal investigator 1 Janssen Research & Development, LLC $254.00 06/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261527
Principal investigator 1 Janssen Research & Development, LLC $350.00 06/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261539
Principal investigator 1 Janssen Research & Development, LLC $824.00 06/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261661
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 06/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261686
Principal investigator 1 ABBVIE INC. $8,000.00 06/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489021
Principal investigator 1 ABBVIE INC. $2,036.80 06/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202489023
Principal investigator 1 ABBVIE INC. $17,027.54 06/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489027
Principal investigator 1 ABBVIE INC. $1,762.94 06/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202489079
Principal investigator 1 Janssen Research & Development, LLC $254.00 06/02/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261107
Principal investigator 1 Janssen Research & Development, LLC $201.00 06/02/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261260
Principal investigator 1 PFIZER INC. $2,695.00 05/30/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228773358
Principal investigator 1 ABBVIE INC. $390.00 05/29/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202486807
Principal investigator 1 PFIZER INC. $4,300.00 05/29/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228771358
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $32,000.00 05/28/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280458
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $32,910.00 05/28/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280460
Principal investigator 1 ABBVIE INC. $1,480.00 05/27/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202486163
Principal investigator 1 ABBVIE INC. $285.42 05/27/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202486165
Principal investigator 1 SANOFI US SERVICES INC. $258.00 05/27/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145835
Principal investigator 1 SANOFI US SERVICES INC. $4,427.60 05/27/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145838
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,654.71 05/23/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280300
Principal investigator 1 Janssen Research & Development, LLC $150.00 05/21/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261403
Principal investigator 1 SANOFI US SERVICES INC. $4,654.68 05/19/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145847
Principal investigator 1 Janssen Research & Development, LLC $3,845.00 05/15/2025 Non-covered Recipient Entity
Apex Derm Mayfield Hts
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175261060
Principal investigator 1 SANOFI US SERVICES INC. $3,828.38 05/12/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145832
Principal investigator 1 ABBVIE INC. $1,459.40 05/08/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202484239
Principal investigator 1 ABBVIE INC. $5,779.26 05/07/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202482517
Principal investigator 1 ABBVIE INC. $17,474.16 05/07/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482543
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,950.00 05/07/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279114
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 05/07/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279116
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,831.05 05/07/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279134
Principal investigator 1 ABBVIE INC. $2,018.04 05/06/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202481265
Principal investigator 1 PFIZER INC. $9,831.22 05/06/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228723066
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $275.00 05/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278898
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 04/28/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260945
Principal investigator 1 Janssen Research & Development, LLC $3,845.00 04/28/2025 Non-covered Recipient Entity
Apex Derm Mayfield Hts
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175261000
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 04/28/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261322
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 04/28/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261469
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 04/28/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261485
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 04/28/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261514
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 04/28/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261590
Principal investigator 1 SANOFI US SERVICES INC. $36,000.00 04/28/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226145819
Principal investigator 1 SANOFI US SERVICES INC. $4,123.18 04/28/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145823
Principal investigator 1 Eli Lilly and Company $5,000.00 04/25/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS OF MARYLAND PA
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1187874995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $330.00 04/25/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278636
Principal investigator 1 ABBVIE INC. $2,400.00 04/24/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202479186
Principal investigator 1 Amgen Inc. $6,445.00 04/24/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246639159
Principal investigator 1 ABBVIE INC. $10,500.00 04/22/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202478325
Principal investigator 1 SANOFI US SERVICES INC. $5,081.00 04/14/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145815
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,475.00 04/11/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277942
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $110.00 04/11/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277944
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,970.56 04/11/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278040
Principal investigator 1 ABBVIE INC. $1,393.20 04/10/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202475828
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $45,597.84 04/09/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis No dispute reported 06/30/2026 1235998985
Principal investigator 1 ABBVIE INC. $1,300.00 04/08/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202474966
Principal investigator 1 PFIZER INC. $1,600.00 04/08/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228778521
Principal investigator 1 SANOFI US SERVICES INC. $1,393.00 04/07/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145765
Principal investigator 1 SANOFI US SERVICES INC. $5,133.58 04/07/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145772
Principal investigator 1 SANOFI US SERVICES INC. $4,632.38 04/07/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145774
Principal investigator 1 SANOFI US SERVICES INC. $665.00 04/07/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145794
Principal investigator 1 Incyte Corporation $500.00 04/04/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1240503198
Principal investigator 1 Incyte Corporation $630.00 04/04/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1240503202
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260867
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260874
Principal investigator 1 Janssen Research & Development, LLC $574.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260906
Principal investigator 1 Janssen Research & Development, LLC $205.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260921
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260938
Principal investigator 1 Janssen Research & Development, LLC $156.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260976
Principal investigator 1 Janssen Research & Development, LLC $205.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261037
Principal investigator 1 Janssen Research & Development, LLC $574.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261053
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261066
Principal investigator 1 Janssen Research & Development, LLC $205.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261082
Principal investigator 1 Janssen Research & Development, LLC $218.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261088
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261131
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261141
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261155
Principal investigator 1 Janssen Research & Development, LLC $218.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261175
Principal investigator 1 Janssen Research & Development, LLC $218.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261196
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261202
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261233
Principal investigator 1 Janssen Research & Development, LLC $205.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261268
Principal investigator 1 Janssen Research & Development, LLC $205.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261333
Principal investigator 1 Janssen Research & Development, LLC $574.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261357
Principal investigator 1 Janssen Research & Development, LLC $574.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261365
Principal investigator 1 Janssen Research & Development, LLC $574.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261372
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261386
Principal investigator 1 Janssen Research & Development, LLC $205.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261413
Principal investigator 1 Janssen Research & Development, LLC $218.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261428
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261445
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261461
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261476
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261498
Principal investigator 1 Janssen Research & Development, LLC $574.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261506
Principal investigator 1 Janssen Research & Development, LLC $205.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261613
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261620
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261629
Principal investigator 1 Janssen Research & Development, LLC $218.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261642
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261656
Principal investigator 1 Janssen Research & Development, LLC $205.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261693
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261703
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/04/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261711
Principal investigator 1 ABBVIE INC. $10,000.00 04/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202472101
Principal investigator 1 ABBVIE INC. $14,739.18 04/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202472104
Principal investigator 1 Janssen Research & Development, LLC $50.00 04/02/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260898
Principal investigator 1 Janssen Research & Development, LLC $824.00 04/02/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261123
Principal investigator 1 SANOFI US SERVICES INC. $3,700.00 04/02/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145761
Principal investigator 1 SANOFI US SERVICES INC. $115.00 04/02/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145809
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,064.06 04/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277492
Principal investigator 1 Janssen Research & Development, LLC $254.00 03/28/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260915
Principal investigator 1 Janssen Research & Development, LLC $150.00 03/28/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260993
Principal investigator 1 Janssen Research & Development, LLC $201.00 03/28/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261213
Principal investigator 1 Janssen Research & Development, LLC $50.00 03/28/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261378
Principal investigator 1 Amgen Inc. $1,500.00 03/25/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) No dispute reported 06/30/2026 1246639151
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 03/24/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260890
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 03/24/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261299
Principal investigator 1 SANOFI US SERVICES INC. $50.00 03/24/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145777
Principal investigator 1 SANOFI US SERVICES INC. $5,184.90 03/24/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145788
Principal investigator 1 Janssen Research & Development, LLC $4,074.00 03/21/2025 Non-covered Recipient Entity
Apex Derm Mayfield Hts
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175261437
Principal investigator 1 Janssen Research & Development, LLC $824.00 03/20/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261677
Principal investigator 1 Janssen Research & Development, LLC $150.00 03/19/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260961
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 03/19/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261074
Principal investigator 1 Janssen Research & Development, LLC $218.00 03/19/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261348
Principal investigator 1 Janssen Research & Development, LLC $2,363.00 03/19/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261395
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 03/19/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261421
Principal investigator 1 Janssen Research & Development, LLC $2,363.00 03/19/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261669
Principal investigator 1 ABBVIE INC. $3,250.00 03/11/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202462407
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 03/10/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145741
Principal investigator 1 ABBVIE INC. $3,771.10 03/07/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202461011
Principal investigator 1 ABBVIE INC. $24,950.00 03/07/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202461136
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,686.40 03/07/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276133
Principal investigator 1 ABBVIE INC. $5,118.80 03/06/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202457931
Principal investigator 1 ABBVIE INC. $4,215.71 03/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202455844
Principal investigator 1 SANOFI US SERVICES INC. $1,044.50 03/04/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145728
Principal investigator 1 SANOFI US SERVICES INC. $2,968.00 03/04/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145782
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 03/03/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226145828
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,929.20 03/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275871
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 02/27/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260860
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 02/27/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260882
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 02/27/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260929
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 02/27/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261242
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 02/27/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261315
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 02/27/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261492
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 02/27/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261567
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 02/27/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261582
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 02/27/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261605
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 02/27/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261634
Principal investigator 1 PFIZER INC. $7,300.00 02/26/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228750295
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $36,566.96 02/26/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275653
Principal investigator 1 SANOFI US SERVICES INC. $9,092.00 02/24/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145786
Principal investigator 1 Janssen Research & Development, LLC $200.00 02/21/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260852
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $45,610.57 02/19/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275391
Principal investigator 1 SANOFI US SERVICES INC. $10,000.00 02/18/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145731
Principal investigator 1 SANOFI US SERVICES INC. $3,828.38 02/18/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145736
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 02/18/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145757
Principal investigator 1 ABBVIE INC. $2,000.00 02/13/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
M19-977 - A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 1202451336
Principal investigator 1 ABBVIE INC. $750.00 02/13/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202451340
Principal investigator 1 SANOFI US SERVICES INC. $10,000.00 02/10/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145805
Principal investigator 1 SANOFI US SERVICES INC. $3,238.55 02/10/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145812
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 02/07/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274985
Principal investigator 1 ABBVIE INC. $11,598.38 02/06/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202448660
Principal investigator 1 PFIZER INC. $3,954.72 02/05/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228751631
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $110.00 02/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274869
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $165.00 02/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274871
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $165.00 02/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274873
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $110.00 02/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274875
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $220.00 02/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274877
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $975.00 02/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274879
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $525.00 02/05/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274881
Principal investigator 1 SANOFI US SERVICES INC. $2,812.20 02/04/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145724
Principal investigator 1 SANOFI US SERVICES INC. $676.00 02/04/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145753
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 02/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274691
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 01/29/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175260953
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 01/29/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261029
Principal investigator 1 Janssen Research & Development, LLC $1,660.68 01/29/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261045
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 01/29/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261099
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 01/29/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261115
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 01/29/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261220
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 01/29/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261451
Principal investigator 1 Janssen Research & Development, LLC $824.00 01/29/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261546
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 01/29/2025 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175261574
Principal investigator 1 Amgen Inc. $190,550.93 01/27/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246639155
Principal investigator 1 Amgen Inc. $115,373.97 01/27/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) No dispute reported 06/30/2026 1246639157
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $305.68 01/27/2025 Non-covered Recipient Entity
Apex Clinical Research
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235998991
Principal investigator 1 SANOFI US SERVICES INC. $4,471.58 01/27/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145744
Principal investigator 1 Incyte Corporation $2,500.00 01/23/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1240503205
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 01/21/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226145748
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $46,209.50 01/16/2025 Non-covered Recipient Entity
Apex Clinical Research Center
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235998987
Principal investigator 1 Janssen Research & Development, LLC $4,265.00 01/16/2025 Non-covered Recipient Entity
Apex Derm Mayfield Hts
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175261744
Principal investigator 1 SANOFI US SERVICES INC. $11,799.60 01/13/2025 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226145800
Principal investigator 1 Eli Lilly and Company $790,405.65 01/08/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS OF MARYLAND PA
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187876213
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.55 01/08/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273807
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $130,278.06 01/03/2025 Non-covered Recipient Entity
Apex Clinical Research Center
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1235998989
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,139.15 01/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273551
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $26.80 01/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273553
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,189.25 01/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273555
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $55.00 01/03/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223273557
Principal investigator 1 ABBVIE INC. $2,018.04 01/02/2025 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202435066